Skip to main content
. Author manuscript; available in PMC: 2018 Feb 8.
Published in final edited form as: Nature. 2017 Apr 26;545(7652):54–59. doi: 10.1038/nature22330

Extended Data Figure 7. Immunocytochemistry and pharmacology in fused hSS-hCS.

Extended Data Figure 7

(a, b, c, d) Representative images of immunostainings for SST, GAD67, GABA, CR, CB in Dlxi1/2b::eGFP+ cells after migration in fused hSS-hCS. (e) Scheme illustrating the pharmacological manipulation of Dlxi1/2b::eGFP+ cells that are migrating in hSS-hCS. (f, g, h, i) Quantification of Dlxi1/2b::eGFP+ cell migration before and after exposure to 100 nM of the CXCR4 antagonist AMD3100 (n= 8 cells from 2 hiPSC lines; paired t-tests, *P= 0.03 for number of saltations, **P= 0.006 for saltation length, **P= 0.006 for speed when mobile, *P= 0.02 for path directness). (j) Plot illustrating the trajectory of Dlxi1/2b::eGFP+ cells in fused hSS-hCS before and after exposure to AMD3100. Data are mean ± s.e.m.